Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, pharmacokinetics and efficacy of ceftobiprole in term
and pre-term newborn babies and infants up to 3 months of age with late-onset sepsis (LOS).
Ceftobiprole is an antibiotic which belongs to a group of medicines called 'cephalosporin
antibiotics'. It is approved for its use to treat adults and children with pneumonia in many
European and non-European countries.